In a report released yesterday, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Arrowhead Research (ARWR), with a price target of $24. The company’s shares closed yesterday at $13.62.
Piros noted:
“We rate Arrowhead Pharmaceuticals Overweight. ARWR utilizes its proprietary TriM to develop targeted drugs based on the RNA interference mechanism that silences disease-causing genes. The company is focused on its subcutaneously (SC) delivered drug candidates in clinical and preclinical development.”
According to TipRanks.com, Piros has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.9% and a 36.9% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.
Arrowhead Research has an analyst consensus of Strong Buy, with a price target consensus of $24.38.
See today’s analyst top recommended stocks >>
Based on Arrowhead Research’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $15.61 million. In comparison, last year the company had a GAAP net loss of $10.73 million.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. Most recently, in October 2018, Peter Brian Leone, the VP, Strategic Bus. Initiatives of ARWR sold 131,137 shares for a total of $1,769,038.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
